Elena Ivanovna Sharova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elena Ivanovna Sharova has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Liubov Olegovna Skorodumova
Medical Genomics Laboratory, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical Biological Agency, 119435 Moscow, Russia
7 shared publications - Anastasia Nikitina
Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
3 shared publications - Edward Viktorovich Generozov
Department of Molecular Biology and Genetics, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia
3 shared publications - Elena Sergeevna Kotova
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
3 shared publications A.O. Vasiliev
Department of Urology, Moscow State Medical Stomatological University, Moscow, Russia
2 shared publicationsA.V. Govorov
Department of Urology, Moscow State Medical Stomatological University, Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 10044
Integrated microRNA and mRNA Profiling in the Corneal Endothelium of Fuchs Endothelial Corneal Dystrophy
MicroRNAs (miRNAs) are endogenous non-coding RNAs that post-transcriptionally modulate gene expression, playing roles in both development and disease pathogenesis. This study specifically investigates the differential miRNA expression in human FECD endothelium compared to healthy controls. By integrating this miRNAome profile with our existing transcriptomic background, we aimed to identify candidate miRNA–target gene regulatory relationships potentially relevant to FECD. NanoString nCounter miRNA profiling was performed on corneal endothelium from FECD patients and controls. Differential expression analysis was conducted, followed by correlation of miRNAs with transcriptomic data from matched samples. Functional enrichment was performed for negatively correlated miRNA–mRNA pairs to identify pathways relevant to FECD pathogenesis. We found 98 differentially expressed miRNAs between FECD and controls. Correlation analysis revealed negatively correlated candidate miRNA–target gene pairs, highlighting potential regulatory interactions. Enrichment analysis of target genes implicated PI3K-AKT, TNF, AGE-RAGE, and focal adhesion pathways as part of FECD molecular alterations. Several dysregulated miRNAs (e.g., miR-302 and miR-630) were associated with processes such as extracellular matrix remodeling, apoptosis, and inflammatory signaling, consistent with key pathogenic features of FECD. This exploratory study provides new insights into the pathogenesis of FECD by integrating miRNA profiling with a transcriptomic background. This combined analysis highlights candidate miRNA–target associations identified within the FECD group and places them into potentially regulatory pathways relevant to endothelial degeneration. The observed miR-29 expression trends are hypothesis-generating; however, the miR-29 family did not meet the prespecified FDR threshold and was not retained in the final correlation network, precluding confirmation of its contribution to ECM remodeling in our cohort. In parallel, comparison with earlier array-based studies revealed inconsistencies that may partly reflect differences in platforms and cohorts; these discrepancies warrant further investigation in independent cohorts. Finally, the analysis of mirtronic host genes uncovered unstable correlations, suggesting that array-based measurements alone are insufficient for reliable miRNA quantification. Together, these findings refine our understanding of FECD-related networks, resolve some earlier contradictions, and open directions for more robust validation and therapeutic exploration.
- 9 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 10044
Open AccessIntegrated microRNA and mRNA Profiling in the Corneal Endothelium of Fuchs Endothelial Corneal Dystrophy
MicroRNAs (miRNAs) are endogenous non-coding RNAs that post-transcriptionally modulate gene expression, playing roles in both development and disease pathogenesis. This study specifically investigates the differential miRNA expression in human FECD endothelium compared to healthy controls. By integrating this miRNAome profile with our existing transcriptomic background, we aimed to identify candidate miRNA–target gene regulatory relationships potentially relevant to FECD. NanoString nCounter miRNA profiling was performed on corneal endothelium from FECD patients and controls. Differential expression analysis was conducted, followed by correlation of miRNAs with transcriptomic data from matched samples. Functional enrichment was performed for negatively correlated miRNA–mRNA pairs to identify pathways relevant to FECD pathogenesis. We found 98 differentially expressed miRNAs between FECD and controls. Correlation analysis revealed negatively correlated candidate miRNA–target gene pairs, highlighting potential regulatory interactions. Enrichment analysis of target genes implicated PI3K-AKT, TNF, AGE-RAGE, and focal adhesion pathways as part of FECD molecular alterations. Several dysregulated miRNAs (e.g., miR-302 and miR-630) were associated with processes such as extracellular matrix remodeling, apoptosis, and inflammatory signaling, consistent with key pathogenic features of FECD. This exploratory study provides new insights into the pathogenesis of FECD by integrating miRNA profiling with a transcriptomic background. This combined analysis highlights candidate miRNA–target associations identified within the FECD group and places them into potentially regulatory pathways relevant to endothelial degeneration. The observed miR-29 expression trends are hypothesis-generating; however, the miR-29 family did not meet the prespecified FDR threshold and was not retained in the final correlation network, precluding confirmation of its contribution to ECM remodeling in our cohort. In parallel, comparison with earlier array-based studies revealed inconsistencies that may partly reflect differences in platforms and cohorts; these discrepancies warrant further investigation in independent cohorts. Finally, the analysis of mirtronic host genes uncovered unstable correlations, suggesting that array-based measurements alone are insufficient for reliable miRNA quantification. Together, these findings refine our understanding of FECD-related networks, resolve some earlier contradictions, and open directions for more robust validation and therapeutic exploration.
- Open Access
- 24 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1)
Latent EBV reactivation drives aberrant B-cell proliferation during ex vivo tumor-infiltrating lymphocyte expansion from EBV-negative rectal cancer tumor tissue
Recent studies underscore herpesvirus-associated risks, especially HHV6 and Epstein–Barr virus (EBV), in CAR-T and tumor-infiltrating lymphocyte (TIL) therapies, partly due to ex vivo cell manipulation. EBV-driven B cell outgrowth can occur during TIL expansion, and EBV-transformed B cells may exert immunomodulatory functions, potentially impacting TIL therapy efficacy and safety — areas that remain underexplored. Here, we characterized a spontaneously arising wild-type EBV-transformed B cell line, lcl_burn0214, established during ex vivo culture of a tumor specimen from a rectal cancer patient who was EBV-negative. The lcl_burn0214 cell line has undergone 70 passages and was confirmed as a monoclonal B cell line of patient origin via HLA genotyping, immunophenotyping (CD19, CD20), B cell receptor clonotype analysis. RNA-seq analysis revealed that lcl_burn0214’s gene expression closely resembles that of lymphoblastoid cells ( r = 0.88) rather than malignant B lymphomas. In immunocompromised mice, lcl_burn0214 exhibited limited tumorigenicity. Autologous TILs were negative for B cells and exhibited a strong interferon-gamma response in the ELISPOT assay during coculture with lcl_burn0214 or with the EBV peptide pool (1000–1800 spots per million of TILs). Our findings underscore the importance of monitoring TIL products for EBV-positive B cell contamination during manufacturing to ensure safety and therapeutic efficacy even for EBV-negative patients.
- 24 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1)
Open AccessLatent EBV reactivation drives aberrant B-cell proliferation during ex vivo tumor-infiltrating lymphocyte expansion from EBV-negative rectal cancer tumor tissue
Recent studies underscore herpesvirus-associated risks, especially HHV6 and Epstein–Barr virus (EBV), in CAR-T and tumor-infiltrating lymphocyte (TIL) therapies, partly due to ex vivo cell manipulation. EBV-driven B cell outgrowth can occur during TIL expansion, and EBV-transformed B cells may exert immunomodulatory functions, potentially impacting TIL therapy efficacy and safety — areas that remain underexplored. Here, we characterized a spontaneously arising wild-type EBV-transformed B cell line, lcl_burn0214, established during ex vivo culture of a tumor specimen from a rectal cancer patient who was EBV-negative. The lcl_burn0214 cell line has undergone 70 passages and was confirmed as a monoclonal B cell line of patient origin via HLA genotyping, immunophenotyping (CD19, CD20), B cell receptor clonotype analysis. RNA-seq analysis revealed that lcl_burn0214’s gene expression closely resembles that of lymphoblastoid cells ( r = 0.88) rather than malignant B lymphomas. In immunocompromised mice, lcl_burn0214 exhibited limited tumorigenicity. Autologous TILs were negative for B cells and exhibited a strong interferon-gamma response in the ELISPOT assay during coculture with lcl_burn0214 or with the EBV peptide pool (1000–1800 spots per million of TILs). Our findings underscore the importance of monitoring TIL products for EBV-positive B cell contamination during manufacturing to ensure safety and therapeutic efficacy even for EBV-negative patients.
- Open Access
- 29 September 2025
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 20 (3) , 241-250
Bioinformatic detection of microsatellite instability using whole transcriptome analysis of colorectal cancer samples
BACKGROUND: Tumor microsatellite instability/microsatellite stability (MSI/MSS) status is a crucial parameter determining both disease prognosis and potential response to immunotherapy. Patients are referred for MSI typing based on clinical indications; however, only a small proportion of patients meet these criteria. Consequently, most sequencing datasets available in repositories and collected locally do not inherently contain MSI information in their metadata. Project funding limitations and insufficient biomaterial quantities often preclude DNA isolation and subsequent MSI typing using polymerase chain reaction methods. RNA sequencing results from tumor tissue may also be used to determine MSI status, but this requires incorporating a bioinformatics tool for MSI assessment into the tumor whole transcriptome analysis protocol. AIM: To evaluate the availability and applicability of bioinformatics tools for determining MSI status in locally derived datasets of whole transcriptomes of colorectal cancer samples. METHODS: Publicly available bioinformatics tools designed for MSI status assessment using RNA sequencing data were selected for analysis. These tools were tested on a locally derived dataset of whole tumor transcriptomes from 13 patients following primary colorectal tumor resection. The number of somatic mutations was assessed as a surrogate marker of MSI/MSS status, along with MSI/MSS status based on the results of bioinformatics tool testing, and their correlation. RESULTS: We tested two bioinformatics tools, PreMSIm and MIRACLE, designed to determine MSI status using transcriptomic data. When using MIRACLE, microsatellite instability was detected in 3 out of 13 samples. The MSI status determined by MIRACLE correlated with tumor mutational burden (TMB) (mean, 2163 mutations in MSI samples vs. 122.9 in MSS samples) and reliably identified unstable samples. PreMSIm also detected MSI in 3 samples, but its results showed limited concordance with TMB. For two of the three samples with high TMB, we identified known pathogenic and likely pathogenic variants in MSH2 and MLH1 genes associated with Lynch syndrome, confirming MSI status. For one sample, we proposed sporadic MSI etiology due to MLH1 gene hypermethylation. CONCLUSION: PreMSIm and MIRACLE demonstrate different sensitivity and specificity profiles for MSI status determination when using TMB as a surrogate MSI/MSS marker in colorectal adenocarcinoma. The MIRACLE tool can be easily integrated into whole-transcriptome tumor analysis protocols and provides biologically plausible MSI/MSS assessments that correlate with transcriptome-derived TMB.
- 29 September 2025
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 20 (3) , 241-250
Open AccessBioinformatic detection of microsatellite instability using whole transcriptome analysis of colorectal cancer samples
BACKGROUND: Tumor microsatellite instability/microsatellite stability (MSI/MSS) status is a crucial parameter determining both disease prognosis and potential response to immunotherapy. Patients are referred for MSI typing based on clinical indications; however, only a small proportion of patients meet these criteria. Consequently, most sequencing datasets available in repositories and collected locally do not inherently contain MSI information in their metadata. Project funding limitations and insufficient biomaterial quantities often preclude DNA isolation and subsequent MSI typing using polymerase chain reaction methods. RNA sequencing results from tumor tissue may also be used to determine MSI status, but this requires incorporating a bioinformatics tool for MSI assessment into the tumor whole transcriptome analysis protocol. AIM: To evaluate the availability and applicability of bioinformatics tools for determining MSI status in locally derived datasets of whole transcriptomes of colorectal cancer samples. METHODS: Publicly available bioinformatics tools designed for MSI status assessment using RNA sequencing data were selected for analysis. These tools were tested on a locally derived dataset of whole tumor transcriptomes from 13 patients following primary colorectal tumor resection. The number of somatic mutations was assessed as a surrogate marker of MSI/MSS status, along with MSI/MSS status based on the results of bioinformatics tool testing, and their correlation. RESULTS: We tested two bioinformatics tools, PreMSIm and MIRACLE, designed to determine MSI status using transcriptomic data. When using MIRACLE, microsatellite instability was detected in 3 out of 13 samples. The MSI status determined by MIRACLE correlated with tumor mutational burden (TMB) (mean, 2163 mutations in MSI samples vs. 122.9 in MSS samples) and reliably identified unstable samples. PreMSIm also detected MSI in 3 samples, but its results showed limited concordance with TMB. For two of the three samples with high TMB, we identified known pathogenic and likely pathogenic variants in MSH2 and MLH1 genes associated with Lynch syndrome, confirming MSI status. For one sample, we proposed sporadic MSI etiology due to MLH1 gene hypermethylation. CONCLUSION: PreMSIm and MIRACLE demonstrate different sensitivity and specificity profiles for MSI status determination when using TMB as a surrogate MSI/MSS marker in colorectal adenocarcinoma. The MIRACLE tool can be easily integrated into whole-transcriptome tumor analysis protocols and provides biologically plausible MSI/MSS assessments that correlate with transcriptome-derived TMB.
- Open Access
- 23 June 2025
- Published by Springer Nature in Research Square
Spontaneous EBV-positive B cell line from rectal tumor: characterization, interaction with autologous tumor-infiltrating T lymphocytes, comparison with B lymphoma cell lines
Recent studies underscore herpesvirus-associated risks, especially HHV6 and Epstein–Barr virus (EBV), in CAR-T and tumor-infiltrating lymphocyte (TIL) therapies, partly due to ex vivo cell manipulation. EBV-driven B cell outgrowth can occur during TIL expansion, and EBV-transformed B cells may exert immunomodulatory functions, potentially impacting TIL therapy efficacy — areas that remain underexplored. Here, we characterized a spontaneously arising wild-type EBV-transformed B cell line, lcl_burn0214, derived from rectal cancer tumor tissue during ex vivo culture. The lcl_burn0214 cell line has undergone 70 passages and was confirmed as a monoclonal B cell line of patient origin via HLA genotyping, immunophenotyping (CD19, CD20), B cell receptor clonotype analysis. RNA-seq analysis comparing EBV-positive and -negative B lymphoma and lymphoblastoid cell lines revealed that lcl_burn0214’s gene expression closely resembles that of lymphoblastoid cells rather than malignant B lymphomas. In immunocompromised mice, lcl_burn0214 exhibited limited tumorigenicity. The cell line expressed immune checkpoint genes (CD274, CSF1, TNFSF4). Nevertheless, autologous TILs were negative for B cells and exhibited specific anti-EBV activity, as demonstrated by the interferon-gamma response in the ELISPOT assay during coculture with lcl_burn0214. Our findings underscore the importance of monitoring TIL products for EBV-positive B cell contamination during manufacturing to ensure safety and therapeutic efficacy.
- 23 June 2025
- Published by Springer Nature in Research Square
Open AccessSpontaneous EBV-positive B cell line from rectal tumor: characterization, interaction with autologous tumor-infiltrating T lymphocytes, comparison with B lymphoma cell lines
Recent studies underscore herpesvirus-associated risks, especially HHV6 and Epstein–Barr virus (EBV), in CAR-T and tumor-infiltrating lymphocyte (TIL) therapies, partly due to ex vivo cell manipulation. EBV-driven B cell outgrowth can occur during TIL expansion, and EBV-transformed B cells may exert immunomodulatory functions, potentially impacting TIL therapy efficacy — areas that remain underexplored. Here, we characterized a spontaneously arising wild-type EBV-transformed B cell line, lcl_burn0214, derived from rectal cancer tumor tissue during ex vivo culture. The lcl_burn0214 cell line has undergone 70 passages and was confirmed as a monoclonal B cell line of patient origin via HLA genotyping, immunophenotyping (CD19, CD20), B cell receptor clonotype analysis. RNA-seq analysis comparing EBV-positive and -negative B lymphoma and lymphoblastoid cell lines revealed that lcl_burn0214’s gene expression closely resembles that of lymphoblastoid cells rather than malignant B lymphomas. In immunocompromised mice, lcl_burn0214 exhibited limited tumorigenicity. The cell line expressed immune checkpoint genes (CD274, CSF1, TNFSF4). Nevertheless, autologous TILs were negative for B cells and exhibited specific anti-EBV activity, as demonstrated by the interferon-gamma response in the ELISPOT assay during coculture with lcl_burn0214. Our findings underscore the importance of monitoring TIL products for EBV-positive B cell contamination during manufacturing to ensure safety and therapeutic efficacy.
- Open Access
- 16 June 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (6) , 875
SLC4A11 Revisited: Isoforms, Expression, Functions, and Unresolved Questions
The SLC4A11 gene encodes a membrane transporter implicated in congenital hereditary endothelial dystrophy, Harboyan syndrome, and certain cancers. Despite its clinical importance, current data on SLC4A11 expression patterns, transcript variants, and functional roles remain inconsistent and sometimes contradictory. We have systematized existing data, identified areas of consensus, and highlighted discrepancies. This review addresses SLC4A11 transcript and isoform diversity and how this complexity influences both the interpretation of its tissue expression patterns (particularly in the corneal endothelium) and the investigation of its functional roles in health and disease. Our review also untangles the evolving understanding of SLC4A11 function, from its initial classification as a bicarbonate transporter to its established roles in NH3- and pH-regulated H+/OH− transport, lactate efflux, cellular stress responses, and adhesion. The review details how pathogenic mutations disrupt protein maturation, membrane localization, or transport activity, contributing to corneal fluid imbalance and disease. We also discuss the emerging role of SLC4A11 in cancer metabolism and the common metabolic features of dystrophic corneas and tumors. Methodological challenges are appraised, encouraging caution in interpretation and the need for isoform-specific studies. Overall, this review provides a comprehensive update on SLC4A11 biology and identifies key gaps for future research.
- 16 June 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (6) , 875
Open AccessSLC4A11 Revisited: Isoforms, Expression, Functions, and Unresolved Questions
The SLC4A11 gene encodes a membrane transporter implicated in congenital hereditary endothelial dystrophy, Harboyan syndrome, and certain cancers. Despite its clinical importance, current data on SLC4A11 expression patterns, transcript variants, and functional roles remain inconsistent and sometimes contradictory. We have systematized existing data, identified areas of consensus, and highlighted discrepancies. This review addresses SLC4A11 transcript and isoform diversity and how this complexity influences both the interpretation of its tissue expression patterns (particularly in the corneal endothelium) and the investigation of its functional roles in health and disease. Our review also untangles the evolving understanding of SLC4A11 function, from its initial classification as a bicarbonate transporter to its established roles in NH3- and pH-regulated H+/OH− transport, lactate efflux, cellular stress responses, and adhesion. The review details how pathogenic mutations disrupt protein maturation, membrane localization, or transport activity, contributing to corneal fluid imbalance and disease. We also discuss the emerging role of SLC4A11 in cancer metabolism and the common metabolic features of dystrophic corneas and tumors. Methodological challenges are appraised, encouraging caution in interpretation and the need for isoform-specific studies. Overall, this review provides a comprehensive update on SLC4A11 biology and identifies key gaps for future research.
- Open Access
- 13 May 2025
- Published by MDPI AG in Preprints.org
SLC4A11 Revisited: Isoforms, Expression, Functions and Unresolved Questions
The SLC4A11 gene encodes a membrane transporter implicated in congenital hereditary endothelial dystrophy, Harboyan syndrome, and certain cancers. Despite its clinical importance, current data on SLC4A11 expression patterns, transcript variants, and functional roles remain inconsistent and sometimes contradictory. We have systematized existing data, identified areas of consensus, and highlighted discrepancies. This review addresses the SLC4A11 transcript and isoform diversity and how this complexity influences both the interpretation of its tissue expression patterns (particularly in the corneal endothelium) and the investigation of its functional roles in health and disease. Our review also untangles the evolving understanding of SLC4A11 function, from its initial classification as a bicarbonate transporter to its established roles in NH3 and pH regulated H+/OH- transport, lactate efflux, cellular stress responses and adhesion. The review details how pathogenic mutations disrupt protein maturation, membrane localization, or transport activity, contributing to corneal fluid imbalance and disease. We also discuss the emerging role of SLC4A11 in cancer metabolism and the common metabolic features of dystrophic corneas and tumors. Methodological challenges are appraised, encouraging caution in interpretation and the need for isoform-specific studies. Overall, this review provides a comprehensive update on SLC4A11 biology and identifies key gaps for future research.
- 13 May 2025
- Published by MDPI AG in Preprints.org
Open AccessSLC4A11 Revisited: Isoforms, Expression, Functions and Unresolved Questions
The SLC4A11 gene encodes a membrane transporter implicated in congenital hereditary endothelial dystrophy, Harboyan syndrome, and certain cancers. Despite its clinical importance, current data on SLC4A11 expression patterns, transcript variants, and functional roles remain inconsistent and sometimes contradictory. We have systematized existing data, identified areas of consensus, and highlighted discrepancies. This review addresses the SLC4A11 transcript and isoform diversity and how this complexity influences both the interpretation of its tissue expression patterns (particularly in the corneal endothelium) and the investigation of its functional roles in health and disease. Our review also untangles the evolving understanding of SLC4A11 function, from its initial classification as a bicarbonate transporter to its established roles in NH3 and pH regulated H+/OH- transport, lactate efflux, cellular stress responses and adhesion. The review details how pathogenic mutations disrupt protein maturation, membrane localization, or transport activity, contributing to corneal fluid imbalance and disease. We also discuss the emerging role of SLC4A11 in cancer metabolism and the common metabolic features of dystrophic corneas and tumors. Methodological challenges are appraised, encouraging caution in interpretation and the need for isoform-specific studies. Overall, this review provides a comprehensive update on SLC4A11 biology and identifies key gaps for future research.
- Open Access
- 3 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3343
From Genes to Disease: Reassessing LOXHD1 and AGBL1’s Contribution to Fuchs’ Dystrophy
Fuchs’ endothelial corneal dystrophy (FECD) is a genetically complex eye disease associated with multiple genes. A recent systematic review has raised concerns about the causal role of variants in the LOXHD1 and AGBL1 genes in the development of FECD. Conflicting data have been reported on the expression of the LOXHD1 and AGBL1 genes in the corneal endothelium. Furthermore, only partial segregation of the variants was observed in familial cases. An analysis of published datasets was conducted to examine the expression of LOXHD1 and AGBL1 genes in normal and FECD-affected corneal endothelia and progenitor cells. Neither LOXHD1 nor AGBL1 genes were expressed in normal or FECD corneal endothelia or progenitor cells. In-house cohorts were screened for carriers of previously reported LOXHD1 and AGBL1 variants. Carriers and their first-degree relatives were invited for an ophthalmological examination to reassess the causal relationship of these variants with FECD phenotype. Three carriers of LOXHD1 variants (one carrier of rs200242497 and two carriers of rs192376005) and two carriers of AGBL1 variants (rs181958589 and rs185919705) were recruited. None of the carriers or first-degree relatives over 50 years exhibited phenotypic signs of FECD via ophthalmic examination. The causal role of the AGBL1 and LOXHD1 variants found in the carriers was not confirmed. Taken together, our findings do not support a causal role for AGBL1 and LOXHD1 in the development of FECD.
- 3 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3343
Open AccessFrom Genes to Disease: Reassessing LOXHD1 and AGBL1’s Contribution to Fuchs’ Dystrophy
Fuchs’ endothelial corneal dystrophy (FECD) is a genetically complex eye disease associated with multiple genes. A recent systematic review has raised concerns about the causal role of variants in the LOXHD1 and AGBL1 genes in the development of FECD. Conflicting data have been reported on the expression of the LOXHD1 and AGBL1 genes in the corneal endothelium. Furthermore, only partial segregation of the variants was observed in familial cases. An analysis of published datasets was conducted to examine the expression of LOXHD1 and AGBL1 genes in normal and FECD-affected corneal endothelia and progenitor cells. Neither LOXHD1 nor AGBL1 genes were expressed in normal or FECD corneal endothelia or progenitor cells. In-house cohorts were screened for carriers of previously reported LOXHD1 and AGBL1 variants. Carriers and their first-degree relatives were invited for an ophthalmological examination to reassess the causal relationship of these variants with FECD phenotype. Three carriers of LOXHD1 variants (one carrier of rs200242497 and two carriers of rs192376005) and two carriers of AGBL1 variants (rs181958589 and rs185919705) were recruited. None of the carriers or first-degree relatives over 50 years exhibited phenotypic signs of FECD via ophthalmic examination. The causal role of the AGBL1 and LOXHD1 variants found in the carriers was not confirmed. Taken together, our findings do not support a causal role for AGBL1 and LOXHD1 in the development of FECD.
- Open Access
- 28 March 2024
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 19 (1) , 169-180
Sudden cardiac death in young athletes: exome sequencing results
BACKGROUND: Ranking risks and prevention of sudden cardiac death in professional young athletes is a crucial unresolved problem in sports medicine. Intense physical exertion can lead to adaptive changes in the cardiovascular system, which can mask inherited diseases with predominant myocardial involvement, such as hypertrophic cardiomyopathy. Undiagnosed cases of such diseases can be a risk factor for fatal outcomes associated with training and competitive activities, making this problem extremely relevant. AIM: To conduct a diagnostic search for possible molecular causes of cardiovascular diseases associated with a high risk of sudden death in young athletes. MATERIALS AND METHODS: Whole-exome sequencing of DNA extracted from two groups of biomaterials was performed: nine autopsy samples of heart tissues from young athletes who died during intense physical exertion and three venous blood samples from active athletes of the Russian national team. Obtained data were subjected to bioinformatic analysis and clinical interpretation. RESULTS: In total, 12 DNA samples were analyzed using a panel of 277 genes associated with the development of cardiovascular diseases with a high risk of sudden death. In 4 of 12 samples (33.3%), variants possibly related to the phenotype were found upon clinical interpretation of the sequencing results. A pathogenic variant was found in the MYBPC3 gene, leading to the development of hypertrophic cardiomyopathy (OMIM: 115197), and a potential pathogenic variant was found in the TRPM4 gene, associated with progressive familial heart block type IB (OMIM: 618531). Moreover, two variants with uncertain clinical significance were found in CAV3 and SCN1B. CONCLUSION: Currently, data from high-throughput sequencing are collected to identify the molecular basis of cardiovascular diseases with a high risk of sudden cardiac death. Identifying young athletes who are carriers of pathogenic and possibly pathogenic gene variants is beneficial for preventing fatal outcomes and personalizing medical support for professional athletes.
- 28 March 2024
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 19 (1) , 169-180
Open AccessSudden cardiac death in young athletes: exome sequencing results
BACKGROUND: Ranking risks and prevention of sudden cardiac death in professional young athletes is a crucial unresolved problem in sports medicine. Intense physical exertion can lead to adaptive changes in the cardiovascular system, which can mask inherited diseases with predominant myocardial involvement, such as hypertrophic cardiomyopathy. Undiagnosed cases of such diseases can be a risk factor for fatal outcomes associated with training and competitive activities, making this problem extremely relevant. AIM: To conduct a diagnostic search for possible molecular causes of cardiovascular diseases associated with a high risk of sudden death in young athletes. MATERIALS AND METHODS: Whole-exome sequencing of DNA extracted from two groups of biomaterials was performed: nine autopsy samples of heart tissues from young athletes who died during intense physical exertion and three venous blood samples from active athletes of the Russian national team. Obtained data were subjected to bioinformatic analysis and clinical interpretation. RESULTS: In total, 12 DNA samples were analyzed using a panel of 277 genes associated with the development of cardiovascular diseases with a high risk of sudden death. In 4 of 12 samples (33.3%), variants possibly related to the phenotype were found upon clinical interpretation of the sequencing results. A pathogenic variant was found in the MYBPC3 gene, leading to the development of hypertrophic cardiomyopathy (OMIM: 115197), and a potential pathogenic variant was found in the TRPM4 gene, associated with progressive familial heart block type IB (OMIM: 618531). Moreover, two variants with uncertain clinical significance were found in CAV3 and SCN1B. CONCLUSION: Currently, data from high-throughput sequencing are collected to identify the molecular basis of cardiovascular diseases with a high risk of sudden cardiac death. Identifying young athletes who are carriers of pathogenic and possibly pathogenic gene variants is beneficial for preventing fatal outcomes and personalizing medical support for professional athletes.
- Open Access
- 14 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (8) , 7297
An Efficient 2D Protocol for Differentiation of iPSCs into Mature Postmitotic Dopaminergic Neurons: Application for Modeling Parkinson’s Disease
About 15% of patients with parkinsonism have a hereditary form of Parkinson’s disease (PD). Studies on the early stages of PD pathogenesis are challenging due to the lack of relevant models. The most promising ones are models based on dopaminergic neurons (DAns) differentiated from induced pluripotent stem cells (iPSCs) of patients with hereditary forms of PD. This work describes a highly efficient 2D protocol for obtaining DAns from iPSCs. The protocol is rather simple, comparable in efficiency with previously published protocols, and does not require viral vectors. The resulting neurons have a similar transcriptome profile to previously published data for neurons, and have a high level of maturity marker expression. The proportion of sensitive (SOX6+) DAns in the population calculated from the level of gene expression is higher than resistant (CALB+) DAns. Electrophysiological studies of the DAns confirmed their voltage sensitivity and showed that a mutation in the PARK8 gene is associated with enhanced store-operated calcium entry. The study of high-purity DAns differentiated from the iPSCs of patients with hereditary PD using this differentiation protocol will allow for investigators to combine various research methods, from patch clamp to omics technologies, and maximize information about cell function in normal and pathological conditions.
- 14 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (8) , 7297
Open AccessAn Efficient 2D Protocol for Differentiation of iPSCs into Mature Postmitotic Dopaminergic Neurons: Application for Modeling Parkinson’s Disease
About 15% of patients with parkinsonism have a hereditary form of Parkinson’s disease (PD). Studies on the early stages of PD pathogenesis are challenging due to the lack of relevant models. The most promising ones are models based on dopaminergic neurons (DAns) differentiated from induced pluripotent stem cells (iPSCs) of patients with hereditary forms of PD. This work describes a highly efficient 2D protocol for obtaining DAns from iPSCs. The protocol is rather simple, comparable in efficiency with previously published protocols, and does not require viral vectors. The resulting neurons have a similar transcriptome profile to previously published data for neurons, and have a high level of maturity marker expression. The proportion of sensitive (SOX6+) DAns in the population calculated from the level of gene expression is higher than resistant (CALB+) DAns. Electrophysiological studies of the DAns confirmed their voltage sensitivity and showed that a mutation in the PARK8 gene is associated with enhanced store-operated calcium entry. The study of high-purity DAns differentiated from the iPSCs of patients with hereditary PD using this differentiation protocol will allow for investigators to combine various research methods, from patch clamp to omics technologies, and maximize information about cell function in normal and pathological conditions.
- 12 February 2023
- Published by Pirogov Russian National Research Medical University in Bulletin of Russian State Medical University
- No. 2023(1),p. 21-29
Podhod k klasterizacii pacientov po mikrochipovym dannym vnutri otdel'nyh lokusov s ispol'zovaniem kombinacij variantov
- 12 February 2023
- Published by Pirogov Russian National Research Medical University in Bulletin of Russian State Medical University
- No. 2023(1),p. 21-29
Podhod k klasterizacii pacientov po mikrochipovym dannym vnutri otdel'nyh lokusov s ispol'zovaniem kombinacij variantov